Among ten patients with HCC receiving immune checkpoint inhibitors (nivolumab or pembrolizumab), only patients who had PD-L1+ CTCs seemed to have any response (all five responders demonstrated PD-L1+ CTCs at baseline, compared with only one of five non-responders) [90]. Here, CD274 is linked to hepatocellular carcinoma.